

Freedom of Information Request

Ref: 22-299

20 June 2022

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we do hold the information you are requesting

Question 1

Please complete the table below:

Radium-223 dichloride service	
Is radium-223 dichloride offered in your trust as a treatment for prostate cancer? (y/n)	Yes
If yes, please list the indications for which it is used in your trust?	Metastatic Castrate Resistant Prostate Cancer as per NICE guidance. Symptomatic Bone only metastases with no known visceral metastases. Both post Docetaxel and pre-Docetaxel where this chemotherapy agent is contraindicated or not suitable for the patient.

Question 2

Please detail the number of patients that are treated with radium-223 dichloride in your trust:

Patient numbers	Numbers provided for 2020-2021 financial year.
Number of prostate cancer patients completing treatment with radium-223 dichloride per year	10
Number of prostate cancer patients initiating radium-223 dichloride treatment per year	38
What is the average number of cycles administered per patient in your service?	4
What is the waiting time before patients can receive radium-223 dichloride?	Minimum of 9 days from consent to ensure blood results and weight available to order radionuclide. Wait times may be longer if patients require dental assessments or other interventions prior to starting.

How many patients are initiated with cabazitaxel per year in your trust?	14
--	----

Question 3

In what department is molecular radiotherapy provided in your trust?

Administration	Radium-223 dichloride	¹⁷⁷ Lutetium based radioligand therapy for neuroendocrine tumours
Nuclear Medicine	Not applicable	Not applicable
Medical Physics	Not applicable	Not applicable
Radiotherapy	Therapeutic radiographer run this service	Therapeutic radiographer run this service
Oncology	Not applicable	Not applicable
Urology	Not applicable	Not applicable
Other	Not applicable	Not applicable
N/A	Not applicable	Not applicable

Question 4

What codes are associated with molecular radiotherapy administration in your trust?

NHS codes	HRG	OPCS code
Radium-223 dichloride	HRG40G	DRUG0208

Question 5

Please complete the table below:

Who performs the administration of the treatment?	Radium-223 dichloride	¹⁷⁷ Lutetium based radioligand therapy for neuroendocrine tumours
CNS	Not applicable	Not applicable
Technician	Not applicable	Not applicable
NM nurse	Not applicable	Not applicable
NM physicist	Not applicable	Not applicable
NM Consultant	Not applicable	Not applicable
Oncologist	Not applicable	Not applicable
Other (<i>please state</i>)	Therapeutic radiographers	Therapeutic radiographers

Question 6

Who holds the ARSAC licence in your trust?

Administration	(y/n)	Radium-223 dichloride	¹⁷⁷Lutetium based radioligand therapy for neuroendocrine tumours
Nuclear Medicine consultant	No		
Clinical Oncologist	Yes	Yes	Yes
Radiologist	No		
Other (please state speciality)	No		

Question 7

Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your trust or are they outsourced?

Radiation safety (y/n)	Conducted in-house <i>(If so, please provide the number of full-time equivalents providing these services in your centre)</i>	Outsourced
Radioactive Waste Adviser (RWA)	Yes 0.8WTE	Not applicable
Radiation Protection Adviser (RPA)	Yes 0.7WTE	Not applicable
Medical Physics Expert (MPE)	Yes 1.8WTE	Not applicable

Question 8

Please complete the table below:

Dosimetry	(y/n)	If yes, what is the schedule after each administration?	If yes, is this analysed in-house or outsourced?
Is dosimetry performed for radium-223 dichloride prostate cancer patients?	No		

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust